Companies › Virogin Biotech
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VG2025 Recombinant human IL-12/IL-15 dual-regulated oncolytic HSV-1 | – | Phase 2 | Intrahepatic Cholangiocarcinoma; Advanced Malignant Solid Tumor | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07522476 | VG2025 | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Jan 2028 |
| NCT07682870 | VG2025 | Phase 1 | Advanced Malignant Solid Tumor | Oncology | Dec 2028 |
No annotated target.
–
NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.